Even the strongest science does not guarantee an investable asset. Here, we discuss how to align early-stage discovery programs for small molecules with investor expectations in a complex biotech funding environment.
New venture capital firm to create and invest in early-stage healthcare companies applying novel technologies to frontier biology and redefine patient care
Radiopharmaceuticals are emerging as the future of cancer care, combining targeted precision with powerful radiation to deliver safer, more effective treatments.
Biotech companies are racing to develop non-opioid pain medications as safer, effective alternatives to addictive opioids, with breakthroughs like Vertex’s FDA-approved Journavx leading a new era in pain management.
Join us in building the future of medicine through innovative technology and biology convergence
